Clinical Trial Update: A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluated safety, tolerability, pharmacokinetics, and dynamic effects of different doses of EMD 525797 in prostate cancer with bone me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Prostate Cancer

Drugs mentioned

• EMD 525797

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Prostate Cancer, Bone Metastases | Phase 1 | Status: COMPLETED | Results posted: 2017-08-02